Herceptin founder snags $158M for his UCLA-biotech partnership TORL BioTherapeutics
One of the key researchers behind identifying HER2 as a breast cancer target — and turning that discovery into what became the blockbuster Herceptin — has formed another biotech with the help of Goldman Sachs, Bristol Myers Squibb, Vertex Ventures HC and other backers.
UCLA’s Dennis Slamon, hematology/oncology division chief at the David Geffen School of Medicine, has put together TORL BioTherapeutics, which disclosed a $158 million Series B Thursday afternoon. The company remained relatively under wraps since 2018, but pushed a couple drugs into the clinic by tapping into nearly $50 million, per a press release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.